sexta-feira, 16 de outubro de 2026
PesquisarExplore
pt.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· October 9, 2026

Presentations.AI, a Beautiful.ai Alternative, Launches Unlimited-Seat Team Plan to Challenge Per-User Pricing, Adding Automatic Brand Sync and Document-to-Presentation Conversion

View original at finance.yahoo.com

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Beautiful.ai provides custom themes, brand controls and shared asset libraries that help organizations keep presentations consistent within an established design system.

    60% confidence

  • Presentations.AI is positioning its platform as an alternative to Beautiful.ai for businesses needing faster brand setup, presentation generation from existing documents and team-wide access without per-seat pricing.

    60% confidence

  • The Presentation Creation Agent learns each user's preferences over time and applies the company's brand identity automatically, keeping presentations consistent across teams.

    60% confidence

  • Brand Sync detects a company's logo, colors and fonts from its website URL and applies that identity across the generated presentation.

    60% confidence

Citado nestas reportagens da Via News

O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,986
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,986 factos verificados com a fonte5,378 documentos-fonte arquivados
Consulte estes dados → isubstrate.com